Neisseria gonorrhoeae vaccines: a contemporary overview
E Williams, KL Seib, CK Fairley… - Clinical Microbiology …, 2024 - Am Soc Microbiol
Neisseria gonorrhoeae infection is an important public health issue, with an annual global
incidence of 87 million. N. gonorrhoeae infection causes significant morbidity and can have …
incidence of 87 million. N. gonorrhoeae infection causes significant morbidity and can have …
Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe
The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region,
especially in the Central and Eastern subregions, are hindered by healthcare disparities …
especially in the Central and Eastern subregions, are hindered by healthcare disparities …
Immune responses to Neisseria gonorrhoeae and implications for vaccine development
Neisseria gonorrheoae is the causative agent of gonorrhea, a sexually transmitted infection
responsible for a major burden of disease with a high global prevalence. Protective …
responsible for a major burden of disease with a high global prevalence. Protective …
4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation
Objectives To evaluate persistence of vaccine effectiveness (VE) and vaccine impact (VI) on
invasive meningococcal B (MenB) disease and gonorrhoea at three years after …
invasive meningococcal B (MenB) disease and gonorrhoea at three years after …
Profiling IgG and IgA antibody responses during vaccination and infection in a high-risk gonorrhoea population
L Stejskal, A Thistlethwaite… - Nature …, 2024 - nature.com
Abstract Development of a vaccine against gonorrhoea is a global priority, driven by the rise
in antibiotic resistance. Although Neisseria gonorrhoeae (Ng) infection does not induce …
in antibiotic resistance. Although Neisseria gonorrhoeae (Ng) infection does not induce …
Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: a case-control study
AR Raccagni, L Galli, V Spagnuolo… - Sexually Transmitted …, 2023 - journals.lww.com
Background We assessed the vaccination effectiveness (VE) of multicomponent
meningococcal serogroup B (4CMenB) vaccine against gonorrhea among people living with …
meningococcal serogroup B (4CMenB) vaccine against gonorrhea among people living with …
The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study
Introduction Diagnoses of gonorrhoea in England rose by 26% between 2018 and 2019.
Recent evidence that a vaccine against meningococcal B disease currently offered to infants …
Recent evidence that a vaccine against meningococcal B disease currently offered to infants …
4CMenB journey to the 10-year anniversary and beyond
The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly
protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 …
protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 …
Association of group B Meningococcal vaccine receipt with reduced Gonorrhea incidence among university students
SG Robison, RF Leman - JAMA Network Open, 2023 - jamanetwork.com
In 2017, New Zealand researchers reported that a meningococcal group B vaccine (MBV)
appeared to reduce gonorrhea incidence, with vaccine effectiveness of 31%. 1 These …
appeared to reduce gonorrhea incidence, with vaccine effectiveness of 31%. 1 These …
Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection
D Nikitin, LK Whittles, JW Imai-Eaton… - The Journal of …, 2025 - academic.oup.com
Background Observational evidence suggests the 4CMenB meningococcal vaccine may
partially protect against gonorrhea, with 1 dose being two-thirds as protective as 2 doses …
partially protect against gonorrhea, with 1 dose being two-thirds as protective as 2 doses …